Parties, docket activity and news coverage of federal case Bristol-Myers Squibb Company et al v. Mylan Pharmaceuticals Inc., case number 1:17-cv-00379, from ...
Feb 7, 2019 ... (all the claims) of United States Patent No. 8,476,239 (“the. '239 Patent”) owned by Bristol-Myers Squibb Company. (“BMS”).1 The ... Momenta Pharm., Inc. v. ... 311 et seq. ... lation for their biosimilar product—they must de-.
Jun 19, 2017 ... OF CALIFORNIA, SAN FRANCISCO COUNTY, ET AL. ... Bristol-Myers Squibb Company (BMS) in California state court, al- leging that the .... Pp. 9–11. (d) BMS's decision to contract with McKesson, a California compa-.
Apr 25, 2017 ... Bristol-Myers Squibb Co. (BMS) is a global pharmaceutical company incorporated in Delaware and headquartered in New York.
Feb 7, 2019 ... ImmunoGen, Inc.; E. I. du Pont de Nemours & Co. v. ... Momenta Pharmaceuticals , Inc. v, Bristol-Myers Squibb Co. ... inter partes review, and covered business method patent review) against a Petitioner ... The case involved a inter partes review (IPR) brought by Momenta against all claims of U.S. Patent No.
Discovery of morpholine-based aryl sulfonamides as Nav1.7 inhibitors. ... Nayak S, Sander O, Al-Huniti N, de Alwis D, Chain A, Chenel M, Sunkaraneni S, ..... ronde « recherche clinique et méthodologie » des Ateliers de Giens XXXIII, d' Andon A, ...... Bethesda (MD): Eli Lilly & Company and the National Center for Advancing ...
Mar 9, 2018 ... Everything about Bristol-Myers Squibb is centered on our patients and ... In 2017, that focus led to strong performance across the company. .... “I had a rash all over my face, my neck, and it was a typical ..... Jose Ponce De Leon-Gonzalez, Senior Packaging Technologist ...... Bristol-Myers Squibb Co., et al.